Navigation Links
China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results
Date:7/10/2008

4,574

Capital and statutory reserves 3,025,794 3,025,794

Total stockholders' equity 44,395,267 23,910,007

Total liabilities and stockholders'

equity $ 93,791,526 $ 44,579,844

CHINA-BIOTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOW

(Audited, amounts expressed in US Dollars)

FOR THE YEARS ENDED MARCH 31, 2008 AND 2007

CASH FLOWS FROM OPERATING ACTIVITIES 2008 2007

Net income 17,542,244 $10,904,986

Adjustment for:

Gain on disposal of plant and

equipment -- (14,793)

Depreciation 999,148 493,472

Change in fair value of convertible

notes (3,366,000) --

(Increase)/Decrease in restricted

cash -- 748,742

(Increase)/Decrease in accounts

receivable 2,261,918 (2,881,034)

(Increase)/Decrease in inventories (154,189) 65,303

(Increase)/Decrease in prepayment (1,418,658) (352,923)

(Increase)/Decrease in other

receivables 2,732

Increase/(Decrease) in accounts

payable 1,036,521 (451,305)

Increase in income tax and surcharge

tax payable 5,008,143 4,186,868

Income tax paid (2,969,765) (2,373,846)

Increase/(Decrease) in other payables

and accruals, and value added tax

payable
'/>"/>

SOURCE China-Biotics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. China-Biotics, Inc. to Present at Chinas 3rd Annual Food Safety Technology Forum 2008
2. China-Biotics, Inc. Announces Conference Call to Discuss Fourth Quarter and Full Year 2008 Results
3. China-Biotics, Inc. to Supply Probiotics to Pharmaceutical Company
4. China-Biotics, Inc. to Present at Two Upcoming Investor Conferences
5. China-Biotics, Inc. Completes Foundation for Its New Plant
6. China-Biotics, Inc. Reports Third Quarter 2008 Financial Results
7. China-Biotics, Inc. Announces Rescheduling of Conference Call to Discuss Third Quarter 2008 Results
8. China-Biotics, Inc. Launches English / Chinese Corporate and Investor Relations Web Site
9. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter FY 2008 Results
10. China-Biotics, Inc. Receives Approval to Begin Construction on Large-Scale Manufacturing Facility
11. China-Biotics, Inc. Launches Shining Probiotics Protein Powder

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...RK, Nov. 30 The Michael... today announced $1.5 million in total awards to s...isease-modifying therapies for Parkinson,s disease...hes to Drug Discovery for Parkinson,s Disease pro...on, plc (NYSE: ELN ), a neuroscience-based biote...
(Date:11/30/2009)...STERDAM, November 30 Biopharmaceut...e first patients have been enrolled in its,multina...The study is,designed to show reduction in transpl...ng an allogeneic stem cell transplantation with a ... patients eligible for an allogeneic,stem cell tra...
(Date:11/30/2009)...LLE, Md., Nov. 30 Novava...mpleted enrollment in the Phase II clinical study ...ommended strains) VLP vaccine candidate in healthy...This randomized, double-blind, active-controlled s...unogenicity of two different doses (15 mcg and 60 ...
(Date:11/30/2009)...EATTLE, Nov. 30 Cell The...nced today that its new class of platinum-based an...rated a stronger anti-tumor potency and activity c...ounds as well as the ability to overcome cisplatin...e presented in a paper titled "Novel Bis-platinum ...
Breaking Biology Technology:The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 3Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 3NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 4New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 3
...aGen to receive approximately $45 million in cash,...ne payments - - Provides updated financ...o be hosted today at 9:00 a.m. EDT -, BRANFORD, C... ), a clinical-stage biopharmaceutical company, an...linostat, a Phase I/II histone,deacetylase inhibit...
...LLE, Calif., April 21 Ortho Evra is an adhesive,t...release 150 mcg of,norelgestromin and 20 mcg of et... It is replaced once a week for three weeks, and n... was approved by the FDA in November,2001, and ove...pproval.,Ortho Evra continues to be marketed aggre...
... Million Net Revenues, $0.03 Net Loss Per Share, ...logies, Inc. (Nasdaq: VNUS ), a leading provider ...tment of venous disease, today announced its,finan... 2008., Net revenues for the first quarter of 200....6 million for the first quarter of 2007. As,expec...
Other Biology Technology:CuraGen Sells Ownership of Belinostat to TopoTarget A/S 2CuraGen Sells Ownership of Belinostat to TopoTarget A/S 3CuraGen Sells Ownership of Belinostat to TopoTarget A/S 4CuraGen Sells Ownership of Belinostat to TopoTarget A/S 5Ortho Evra Patch Makers Settling Cases 2VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 2VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 3VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 4VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 5VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 6VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 7
(Date:11/30/2009)..., New Orleans, LA Researchers from LSU Health Sc... Eunice Kennedy Shriver National Institute of Chil...hool of Public Health, Brigham and Women,s Hospita...first time that drinking more than 5 servings of s...ears to significantly elevate the risk of developi...
(Date:11/30/2009)..., Two so-called invasion proteins are crucial for...surface of human cells, which stimulates the host ...ptor molecules exert a different function, for exa...ng. The group,s results have now been published in...iology ". , Spoiled meat is one of the sources f...
(Date:11/30/2009)..., If you ever thought the stress of seeing your e...g youbad news: a new research report in the Decemb...iology ( http://www.jleukbio.org ) shows that you...m the same study might lead to entirely new treatm..., arthritis, and eczema under control. That,s beca...
Breaking Biology News(10 mins):Sugary cola drinks linked for first time to higher risk of gestational diabetes 2Sugary cola drinks linked for first time to higher risk of gestational diabetes 3It takes 2 to infect 2Seeing family for the holidays? Scientists discover how the stress might kill you 2UCR scientists manipulate ripples in graphene enabling strain based graphene electronics 13195 1UCR scientists manipulate ripples in graphene enabling strain based graphene electronics 13195 2UCR scientists manipulate ripples in graphene enabling strain based graphene electronics 13195 3Surgery remans an option for advanced lung cancer 52719 1Surgery remans an option for advanced lung cancer 52719 2Common allergy drug reduces obesity and diabetes in mice 9359 1Common allergy drug reduces obesity and diabetes in mice 9359 2Common allergy drug reduces obesity and diabetes in mice 9359 3Common allergy drug reduces obesity and diabetes in mice 9359 4
...rcent of women rely on their healthcare providers ...ercent said their doctor has talked to them about ...avirus (HPV) - according to a new survey released ...onals (ARHP). HPV is extremely common, affecting a...n their lifetime, in some cases staying dormant un...
...r manipulating macromolecules has been developed b...ana-Champaign. The technique uses double-stranded ...In previous DNA nanotechnology efforts, duplex DNA...ometrical objects in three dimensions. Instead of ...rchers are using DNA to control the folding and re...
...r manipulating macromolecules has been developed b...ana-Champaign. The technique uses double-stranded ...In previous DNA nanotechnology efforts, duplex DNA...ometrical objects in three dimensions. Instead of ...rchers are using DNA to control the folding and re...
Other Biology News:Survey reveals women and doctors aren't talking about HPV 2Survey reveals women and doctors aren't talking about HPV 3Health costs soar as 60 million Americans classed as obese 2UN successfully tests 'green' pesticide against locusts 2
Goat Anti-Human SCP3 / SYCP3 Affinity Purified Polyclonal Antibody, Unconjugated from R&D Systems
Rabbit Anti-Human ADH5 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Mouse Anti-Human Rad1 Monoclonal Antibody, Unconjugated, Clone 33 from R&D Systems
Cytological Nuclear Counterstain Kit - DAPI/SYTOX Green/PI - 300 slides from Molecular Probes (Invitrogen)
Biology Products: